ArticleCancer cell international2025
Neuro-oncological ventral antigen 1 regulates liver cancer stem cell properties and Lenvatinib resistance via targeting SOX4.
Article in Cancer cell international, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer stem cells (CSCs) are essentially linked with the pathogenesis of human cancers. It has been reported that RNA binding protein modulates the stemness of CSCs. This investigation identified that in CSCs, NOVA1 is upregulated. Knockdown of NOVA1 inhibits tumorigenesis and self-renew ability of liver CSCs, whereas its forced expression has opposite effects. The mechanistic analysis revealed that in liver CSCs, SOX4 is a direct NOVA1 target. It enhances tumorigenesis and self-renew ability of liver CSCs by increasing SOX4 mRNA stability by combing with the 3-'UTR. Furthermore, NOVA1 overexpression desensitizes hepatocellular carcinoma (HCC) cells to Lenvatinib-mediated cell development suppression and apoptosis. Patients' cohort analysis indicated that low NOVA1 might predict the benefits of Lenvatinib in HCC individuals. Moreover, knocking down SOX4 could reverse the NOVA1 overexpression-mediated desensitization of HCC cells to Lenvatinib-induced cell apoptosis. In summary, this investigation indicates the essential role of NOVA1 self-renew of CSCs and tumorigenesis in the liver, suggesting it as an optimal HCC therapeutic target.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.